Clinical Context
A 68-year-old male with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel presents for second-line systemic chemotherapy with cabazitaxel. The patient arrives to an outpatient oncology infusion center for evaluation by the oncology team, nurse intake, and baseline labs (CBC, CMP) before administration. The oncology advanced practice provider confirms indication, reviews prior chemo tolerance, documents performance status, obtains informed consent, and verifies premedication orders (antiemetic, corticosteroid, antihistamine) and growth factor plan if indicated.
On the day of service the chemotherapy is prepared by pharmacy using J9043 (cabazitaxel, 1 mg) dosed per body surface area and vial concentration. The infusion nurse performs IV access assessment, administers premedications, and initiates cabazitaxel infusion through an infusion pump over the facility’s standard infusion time. The patient is monitored for infusion reactions and cytopenias; vitals are recorded baseline and periodically during the infusion. Post-infusion, the nurse documents drug lot and amount administered, disposes of hazardous waste per policy, and schedules the next cycle. Billing uses J9043 reported per milligram with payer-appropriate units, and modifiers are appended when necessary to indicate circumstances such as billing practitioner, administration location, or specific payment adjustments.